Amarin Corp Plc (AMRN)

[Jamaalish]

Airbaa, this is a small approval-stage single-drug development company on a relative shoe-string budget and limited revenue. Speculation, binary events, paranoia, buyout fever, shorting, capital raises, and crazy unexplainable price movements maybe should be expected. I would't be surprised of much of the fall in price after this secondary offering and the one in the fall was caused by lowered expectations of a buyout. Anyway it's not a mature drug company. Maybe your expectations are too big or too early?

I'm guessing JT is in it for the long term, full speed ahead and short-term prices be damned. Until we make it to post-FDA approval it will be interesting and even afterwards, but hopefully less so.

JT has us in great position, at the threshold of a huge event, with full control over the company and over a drug with enormous potential, with cash on hand and the backing of influential investment banks if we need to get more or make deals. With no debt and no restrictions. With priority review from the FDA and the Canadian version of the FDA, and with support in the medical community including the ADA SOC guidelines, and with encouraging sales numbers.